Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB26FDQDV
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,357
Award facts
- Contract value 100% obligated
- $11,357.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,357.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/mL auto-injector medication. The award was issued on October 23, 2025, with an ultimate completion date of October 24, 2025, utilizing firm fixed-price pricing with no set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion government-wide acquisition strategy that establishes multiple regional prime vendor contractors to supply the Department of Defense medical system with comprehensive pharmaceutical products and medical consumables.
DMS Pharmaceutical Group Inc. has demonstrated substantial performance as a critical pharmaceutical supplier to federal military healthcare facilities, with numerous delivery orders issued by DLA's Medical Supply Chain division spanning diverse therapeutic categories including oncology treatments, immunosuppressants, biologics, vaccines, and specialty pharmaceuticals. The company's PPV-G GEN V prime vendor contract, awarded in November 2025 with a ceiling value of $499,999,999 and completion date of December 31, 2036, positions it to serve Department of Defense healthcare operations globally through a 30-month base period with three optional 30-month renewal periods. No subcontractors were identified on this delivery order, with the company serving as the sole contractor responsible for pharmaceutical supply fulfillment.
Quick answers
Who was awarded contract SPE2DB26FDQDV?
SPE2DB26FDQDV was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 23, 2025.
How much is contract SPE2DB26FDQDV worth?
The government has obligated $11,357 on SPE2DB26FDQDV.
Is contract SPE2DB26FDQDV an order under another contract?
Yes. SPE2DB26FDQDV is a delivery order under SPE2DB24D9238, an indefinite delivery contract.
Was contract SPE2DB26FDQDV competed?
The extent of competition for SPE2DB26FDQDV was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award